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The activation of CD4+ T helper cells is strictly dependent on the presentation of antigenic
peptides by MHC class II (MHC-II) molecules. MHC-II expression is primarily regulated at
the transcriptional level by the AIR-1 gene product CIITA (class II transactivator). Thus,
CIITA plays a pivotal role in the triggering of the adaptive immune response against
pathogens. Besides this well known function, we recently found that CIITA acts as an
endogenous restriction factor against HTLV-1 (human T cell lymphotropic virus type 1)
and HTLV-2 oncogenic retroviruses by targeting their viral transactivators Tax-1 and Tax-2,
respectively. Here we review our ﬁndings on CIITA-mediated inhibition of viral replication
and discuss similarities and differences in the molecular mechanisms by which CIITA
speciﬁcally counteracts the function ofTax-1 andTax-2molecules.The dual function of CIITA
as a key regulator of adaptive and intrinsic immunity represents a rather unique example
of adaptation of host-derived factors against pathogen infections during evolution.
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INTRODUCTION
Adaptive and innate immune responses represent the most power-
ful tool used by the host to counteract infectious agents. Additional
intrinsic defense systems against viral infections have been recently
identiﬁed. They include host-encoded restriction factors, ini-
tially described for their inhibitory effect on immunodeﬁciency
virus type 1 (HIV-1) infection (reviewed in Wolf and Goff,
2008), such as apolipoprotein B mRNA-editing catalytic polypep-
tides (APOBECs; Sheehy et al., 2002; Chiu and Greene, 2008;
Refsland and Harris, 2013), TRIM (tripartite motif) family mem-
bers (Stremlau et al., 2004; Ozato et al., 2008; Fletcher and Towers,
2013), tetherin (Neil et al., 2008; Kuhl et al., 2011), and sterile alpha
motif (SAM) and HD domain-containing protein 1 (SAMHD1)
(Laguette et al., 2011; Sharkey, 2013). Most of these anti-viral pro-
teins were uncovered through the discovery of viral factors that
counteract their function, implying that viruses are resistant to the
restriction factors of their natural hosts. Although these ﬁndings
suggested a cross-species restriction, further studies demonstrated
that restriction factors may limit pathogenicity in vivo even in
their speciﬁc host (reviewed in Ross, 2009). Besides HIV, the phe-
nomenon of viral restriction has been investigated in other viral
infections including oncogenic human T cell lymphotropic virus
type 1 (HTLV-1) infection. HTLV-1 was the ﬁrst human onco-
genic retrovirus to be discovered (Poiesz et al., 1980). HTLV-1 is
closely related to the less pathogenic HTLV-2 virus. The genomes
of these viruses code for similar structural, enzymatic, and regu-
latory proteins (Franchini, 1995; Nicot et al., 2005). Among them,
the transcriptional activators, named Tax-1 (HTLV-1) and Tax-2
(HTLV-2) share roughly 77% amino acid sequence homology and
have conserved functional regions. Both viruses infect primarily
T lymphocytes, but their infection is associated with different dis-
ease manifestations. HTLV-1 is the etiologic agent of an aggressive
formof adult T cell leukemia/lymphoma (ATLL), of a neurological
disorder designated HTLV-1-associated myelopathy/tropical spas-
tic paraparesis (HAM/TSP) and inﬂammatory disorders (Yoshida
et al., 1982; Uchiyama, 1997; Mahieux and Gessain, 2003). Tax-1
plays a major role in the onset of leukemogenesis by regulating
cell cycle progression, cell growth, apoptosis, and DNA repair
(Feuer and Green, 2005; Hall and Fujii, 2005; Kashanchi and
Brady, 2005; Matsuoka and Jeang, 2007; Yasunaga and Matsuoka,
2011). HTLV-2 has been linked to HAM/TSP “like” cases, whereas
no clear epidemiological link to lymphoproliferative malignan-
cies has been demonstrated (Lehky et al., 1996; Roucoux and
Murphy, 2004). Comparative studies of Tax-1 and Tax-2 func-
tions brought to light major phenotypic differences in their viral
transactivating capacity, transforming activity, modulation of
cellular genes expression, and subcellular localization (Semmes
et al., 1996; Tanaka et al., 1996; Endo et al., 2002; Sieburg et al.,
2004; Shoji et al., 2009; Bertazzoni et al., 2011; Rende et al., 2012;
Turci et al., 2012).
Studies on the role of restriction factors in HTLV-1 infec-
tion are controversial. HTLV-1 replicates in the same cells as
HIV-1 and it does not express an accessory protein analogous
to HIV-1 Vif that inactivates hAPOBEC3G. Nevertheless, HTLV-1
seems to be relatively resistant to hAPOBEC3 proteins (Mahieux
et al., 2005; Ohsugi and Koito, 2007). Derse et al. (2007) have
shown that resistance of HTLV-1 to hAPOBEC3G is mediated
by the C-terminus of gag, which seems to exclude hAPOBEC3G
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from virions. Other reports have shown that hAPOBEC3G is
packaged into HTLV-1 particles, but with opposite effects on
virion infectivity (Navarro et al., 2005; Sasada et al., 2005). Inter-
estingly, it has been hypothesized that non-sense mutations in
viral genes induced by hAPOBEC3G might allow the virus to
escape the host immune response (Fan et al., 2010). Studies
related to a possible effect of tetherin on HTLV-1 infectivity
indicated that tetherin reduces cell-free infectivity of HTLV-1
with a minor effect on cell-to-cell transmission (Ilinskaya et al.,
2013). Finally, evidence of HTLV-1 resistance to SAMHD1-
mediated restriction have been recently reported (Gramberg et al.,
2013).
Another cellular protein with anti-viral function is the MHC
class II (MHC-II) transactivator, also designated CIITA (class II
transactivator). The gene encoding CIITA and the elucidation of
its function as the master regulator of MHC-II gene transcrip-
tion and, thus, of antigen presentation to CD4+ T helper cells
(TH) were ﬁrst discovered in our laboratory (Accolla et al., 1986).
Upon antigen recognition TH cells coordinate both humoral and
cellular immune responses to eradicate pathogen infections and
ﬁght tumors (Accolla and Tosi, 2012). This prominent role of
CIITA in the homeostasis of the immune system has emerged
from the elucidation of the molecular defect at the basis of the
bare lymphocyte syndrome (BLS), a severe form of combined
immunodeﬁciency, characterized by the loss of expression of
MHC-II molecules (Yang et al., 1988; Steimle et al., 1993; Reith
and Mach, 2001). CIITA is a protein of 1130 amino acids localized
in both the nucleus and the cytoplasm; it contains four func-
tional domains: the N-terminal transcription activation domain
(AD); the proline/serine/threonine-rich region (P/S/T); the GTP-
binding domain (GBD), and the C-terminal leucine-rich repeats
(LRR) that are critical for the subcellular distribution of the pro-
tein (Cressman et al., 2001). The integrity of CIITA domains
is critical for the activation function on the MHC-II promoter.
CIITA regulates MHC-II gene expression by coordinating sequen-
tial steps of the transcription process from the assembly of the
general transcriptional machinery and the recruitment of coac-
tivators and chromatin remodeling factors, to the binding of
transcription elongation factors (Fontes et al., 1999a). CIITA is
recruited to MHC-II promoters via the interaction with DNA-
bound factors including the regulatory factor X (RFX) complex
and the trimeric NF-Y complex (Caretti et al., 2000; De Sandro
et al., 2000; Masternak et al., 2000; Zhu et al., 2000; Jabrane-
Ferrat et al., 2002, 2003). Both constitutive and IFNγ-inducible
expression of MHC-II is controlled by CIITA, whose gene is
regulated at transcriptional level by three distinct promoters
driving CIITA expression in different cell lineages (Reith et al.,
2005).
Several years ago, we discovered that CIITA restricts HIV-1
infection by acting at the level of viral replication. The molecu-
lar mechanism at the basis of this inhibition is the competition
between CIITA and HIV-1 Tat transactivator for the cyclin T1
subunit of the elongation complex P-TEFb (positive transcription
elongation factor b; Accolla et al., 2002). In this review we summa-
rize our knowledge of the role of CIITA as a restriction factor for
HTLV-1 and HTLV-2 viruses. We discuss the results on the inhi-
bition of Tax-1 and Tax-2 functions by CIITA and concentrate on
novel insights into the mechanisms through which CIITA operates
this suppressive function.
CIITA INHIBITS BOTH HTLV-1 AND HTLV-2 VIRAL
REPLICATION
Beside inhibitingHIV-1 transcriptional elongation,CIITA inhibits
also the replication of HTLV-1 and HTLV-2. As far as HTLV-1,
we demonstrated that exogenously expressed CIITA in 293T cells
transfected with the HTLV-1 molecular clone pACH resulted in
strong inhibition of HTLV-1 virus production. More importantly,
in promonocytic cells endogenously expressed CIITA produced
the same effect (Tosi et al., 2011). Two phenotypically and func-
tionally distinct clones of the promonocytic U937 cell line,
named Minus and Plus, previously characterized for their inef-
ﬁcient or efﬁcient capacity to support productive HIV-1 infection,
respectively (Franzoso et al., 1994), were studied. Interestingly,
we found that the Minus clone expresses CIITA and MHC-II,
whereas the Plus clone does not express either. Minus and Plus
clones were transfected with the pACH plasmid and assessed
for viral expression by measuring p19 antigen in the cell super-
natants. Remarkably, and similarly to what observed with the
HIV-1 infection, we found that the two clones had a different
behavior with respect to HTLV-1 infection. The p19 levels were
drastically reduced in the supernatants of CIITA-positive Minus
clone, compared with the CIITA-negative Plus clone. Moreover,
the stable expression of CIITA in the Plus clone after transfec-
tion with CIITA cDNA, reverted its permissive phenotype to
the Minus-like non-permissive one (Figure 1A), demonstrat-
ing that CIITA is a major restriction factor for HTLV-1. As far
as HTLV-2 infection, we found that cells of both the T- and
B-lineage are less permissive to HTLV-2 replication in the pres-
ence of CIITA. In particular, by using the isogenic B cell system,
consisting of CIITA-positive Raji cells and its CIITA-negative
derivative RJ.2.2.5 (Accolla, 1983), it was found that RJ.2.2.5
sustained very high levels of virus replication, whereas a pro-
found inhibition of viral replication was observed in Raji parental
cells, although both cell lines were equally infected by HTLV-2.
Thus, physiologic levels of CIITA were able to strongly inhibit
HTLV-2 expression. Consistent with this observation, the per-
missive RJ2.2.5 cells stably transfected with CIITA cDNA became
refractory to HTLV-2 replication showing almost undetectable
levels of p19 antigen upon viral infection (Casoli et al., 2004,
Figure 1B).
Overall, our observations indicated that physiologic amounts
of CIITA may inhibit viral expression in cells that are natural
target of HTLV-1 and HTLV-2 infection, suggesting that in vivo
the virus may replicate preferentially in cells lacking CIITA. In
this regard, it is interesting that during dendritic cell (DC) mat-
uration induced by different stimuli (LPS, CD40L, Sendai virus,
Salmonella typhimurium, IFNα, and TNFα), the expression of
MHC-II molecules is increased due to an enhanced transport
of preformed molecules to the cell surface. In contrast, de novo
biosynthesis of MHC-II mRNA is shut off because of the epige-
netic silencing of CIITA gene (Landmann et al., 2001). Thus, it
is conceivable that a similar CIITA silencing might occur in DC
infected by HTLV-1 allowing viral replication and spreading to
CD4+ T cells (Jones et al., 2008).
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FIGURE 1 | Endogenous CIITA inhibits both HTLV-1 and HTLV-2 gene
expression. (A) CIITA-negative U937 plus clone, CIITA-positive U937
minus clone, and U937 plus clone stably expressing fCIITA (U937 plus
fCIITA) were transfected with the pACH plasmid containing the entire
HTLV-1 genome. The amount of HTLV-1 p19 antigen (pg/ml) in cells
supernatants was detected by enzyme-linked immunoassay (ELISA) 48 h
post-transfection. Error bars indicate standard deviations. Derived fromTosi
et al. (2011). (B) CIITA-positive Raji cells, their CIITA-negative isogenic
mutant RJ2.2.5, and the RJfCIITA cells stably transfected with CIITA were
infected with the HTLV-2 Gu strain 2b and the productive infection was
evaluated by the presence of HTLV-2 p19 antigen (pg/ml) in cell culture
supernatants measured by (ELISA). Error bars indicate standard deviations.
Derived from Casoli et al. (2004).
CIITA TARGETS Tax-1 AND Tax-2 TRANSACTIVATORS TO
INHIBIT VIRAL EXPRESSION
In searching for the molecular mechanisms through which CIITA
inhibits HTLV-1 and HTLV-2 viral replication, we found that
CIITA targets the viral transactivators Tax-1 and Tax-2. Indeed, we
showed that exogenous CIITA could inhibit the Tax-1- and Tax-
2-mediated HTLV LTR transactivation in LTR-driven luciferase
gene reporter assays (Casoli et al., 2004; Tosi et al., 2006, 2011;
Orlandi et al., 2011). By using several CIITA deletion mutants, the
N-terminal region 64–144 was found to be minimally necessary to
inhibit both Tax-1 and Tax-2 function (Figure 2).
Accordingly, HTLV-2 replication was found to be strongly sup-
pressed in RJ.2.2.5 B cells stably transfected with the N-terminal
1–321 fragment of CIITA, which localizes mostly in the nucleus.
In contrast, the cytoplasmic mutant CIITA 322–1130, which does
not contain the minimal inhibitory domain, did not signiﬁcantly
inhibit HTLV-2 expression (Tosi et al., 2006).
Similarly, cytoplasmic CIITA mutants containing the region
64–144 and partially and /or temporarily accumulating in the
nucleus, inhibited Tax-1 transactivation. This was observed with a
mutant having the internal deletion of the region 253–410 mediat-
ing dimerization of CIITA (Tosi et al., 2002) and accumulating in
the nucleus after treatmentwith LeptomycinB (LMB),an inhibitor
of CRM1-mediated nuclear export. Importantly, the study of this
mutant in relation to Tax-1 inhibition, provided new insights on
the cellular biology of CIITA. For the ﬁrst time, phosphorylation-
dependent dimerization of CIITA has been deﬁned as a critical
post-translationalmodiﬁcation (PTM) required forCIITAnuclear
retention and, thus, transcriptional activity on MHC-II promoters
FIGURE 2 | Schematic representation of CIITA regions involved in
the suppression ofTax function and in CIITA-Tax association. At the
top is a diagram of CIITA with its domains: AD, activation domain; P/S/T,
proline/serine/threonine-rich domain; GBD, GTP-binding domain; and LRR,
leucine-rich repeats. The black box represents the minimal domain from
positions 64–144 that is necessary to block the transcription function of
Tax (Tax-inhibition, middle). Hatched (positions 1–252) and gray (positions
253–410) boxes represent the two regions of CIITA interacting with Tax
(Tax interaction, bottom).
(Tosi et al., 2011). However, because full length CIITA has a dual
nuclear and cytoplasmic localization, our ﬁndings do not exclude
that CIITA might also inhibit Tax in the cytoplasm. Studies are in
progress to assess whether cytoplasmic CIITA mutants containing
the N-terminal inhibitory region, still inhibit Tax. These experi-
ments will clarify whether CIITA exerts its suppressive function on
Tax in both the nucleus and the cytoplasm, potentially revealing a
more complex picture, as CIITA might exploit distinct molecular
mechanisms to inhibit Tax in the two cellular compartments.
This will be particularly relevant for Tax-2, which, differ-
ently from Tax-1, exhibits a predominant cytoplasmic distribution
with some accumulation in nuclear bodies (Meertens et al., 2004a;
Sheehy et al., 2006; Turci et al., 2009).
A relevant ﬁnding of our studies, instrumental in understand-
ing the complex picture of the CIITA-mediated inhibition of Tax-1
and Tax-2 function, was the demonstration of the in vivo molec-
ular interaction between CIITA and Tax-1/Tax-2 (Orlandi et al.,
2011; Tosi et al., 2011). Since CIITA is localized predominantly
in the nucleus but also to a lesser extent in the cytoplasm, one
possible scenario is that the cytoplasmic fraction of CIITA could
bind Tax itself or a cellular factor crucial for Tax transactivation,
inhibiting their nuclear translocation. Intriguingly, our interac-
tion studies revealed that CIITA associates in vivo with Tax-1 and
Tax-2 by using two adjacent regions at the N-terminus (Figure 2).
The region 1–252 mediates both the binding to the transactivators
and their functional inhibition, whereas the region 253–410 binds
to, but does not inhibit Tax proteins (Orlandi et al., 2011; Tosi
et al., 2011). We suggested that the two regions form a single Tax-
interacting surface in the context of the entire CIITA molecule,
but only the presence of the minimal domain 64–144 confers
inhibitory properties to this association. Tax-1 region involved
in this interaction spans amino acids sequence 1 to 108, includ-
ing the CREB (cAMP response element-binding protein)-binding
domain (Adya and Giam, 1995; Goren et al., 1995; Tosi et al.,
2011). In searching for similar or distinct mechanisms of CIITA-
mediated inhibition of Tax-1 and Tax-2, future experiments will
assess whether CIITA binds the same N-terminal region of Tax-2.
Of note, CIITA-Tax interaction was not observed with proteins
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produced in vitro (data not shown) indicating that a bridging cell
factor might play a role in this interaction or that PTM, that do
not occur in vitro, are crucial to promote the binding. Many stud-
ies have shown that sumoylation, ubiquitination, acetylation, and
phosphorylation play a critical role in the subcellular localization,
protein–protein interaction and function of both Tax-1 and Tax-2,
revealing similarities and differences between the two transacti-
vators (Bex et al., 1999; Chiari et al., 2004; Lamsoul et al., 2005;
Durkin et al., 2006; Nasr et al., 2006; Gatza et al., 2007; Lodewick
et al., 2009; Turci et al., 2009; Bidoia et al., 2010; Bertazzoni et al.,
2011; Journo et al., 2013). In addition, dimerization of Tax-1 is
necessary for its nuclear localization and interaction with CREB
and the 21-bp repeat elements (Tie et al., 1996; Jin and Jeang, 1997;
Basbous et al., 2003; Fryrear et al., 2009). Similarly, we previously
described that CIITA expressed in cells, but not CIITA produced
in vitro, formshomodimers in aphosphorylation-dependentman-
ner (Tosi et al., 2002) and this modiﬁcation is a prerequisite to
CIITAnuclear retention (Tosi et al., 2011). Nevertheless, the inabil-
ity of CIITA to interact with Tax in vitro cannot be ascribed to the
incapacity of CIITA to self-associate in vitro, because, as men-
tioned above, the dimerization-deﬁcient CIITA253–410 mutant
retains the ability to inhibit Tax-1 in vivo. Other modiﬁcations
of CIITA, including acetylation, deacetylation, and ubiquitination
(Spilianakis et al., 2000; Wu et al., 2009 and references therein),
might have a major role in Tax-1-binding. Such PTMs have been
reported to affect the interaction of CIITA with cellular factors
involved in MHC-II transcription (Greer et al., 2003) and the
recruitment of either corepressors or coactivators on different pro-
moters (Xu et al., 2008; Wu et al., 2009). PTMs-defective forms of
both Tax and CIITA will be crucial to determine the potential role
of speciﬁc modiﬁcation in Tax-binding and/or functional inhibi-
tion. For instance, we have evidence that Tax-1 interacts with both
the hypo- and the hyper-phosphorylated forms of CIITA (data not
shown).
Overall, our ﬁndings suggest that CIITA-mediated inhibition
of Tax activity could rely on the physical association between the
two factors. We know that this binding occurs off DNA, but it
is still unclear whether Tax–CIITA complexes are recruited on
the HTLV LTR (Figure 3A). If this were case, two hypotheses
are equally plausible. Tax bound to CIITA is not assembled on
the viral promoter and this correlates with the inhibition of Tax-
mediated LTR activation (Figure 3B). Alternatively, the binding
of CIITA to Tax could still permit its recruitment on the LTR,
but not its transcription function. CIITA might prevent the inter-
action of Tax with components of the transcriptional machinery
required for HTLV LTR transactivation (Figure 3C). In this con-
text, it is intriguing that, as discussed below, the direct interaction
of Tax-1 with PCAF (P300/CBP-associated factor), which coop-
erates with Tax-1 to activate transcription from the LTR (Jiang
et al., 1999), is severely impaired in the presence of CIITA (Tosi
et al., 2011). To discriminate between the two above hypotheses,
ChIP/EMSA assays are required. However, our subcellular distri-
bution studies of Tax proteins in the presence of CIITA seem to
favor the ﬁrst mechanism. Tax-2 colocalizes with CIITA in the
cytoplasm with a characteristic accumulation around the nuclear
membrane potentially contributing to Tax-2 loss of function.
Interestingly, Tax-2 does not respond by itself to LMB treatment
FIGURE 3 | CIITA-Tax interaction might differently affectTax-mediated
activation of the viral LTR promoter. (A) In the absence of CIITA, Tax-1 is
recruited by CREB to the viral LTR and promote the formation of an higher
order multiprotein complex activating transcription. (B) CIITA bindsTax and
prevents its recruitment to the LTR promoter. (C)Tax bound to CIITA is
recruited to the LTR, but its transcription function is impaired.
(Chevalier et al., 2005); however, in cells treated with LMB, CIITA
recruits Tax-2 into the nucleus (Orlandi et al., 2011). This sug-
gests that CIITA exerts a driving force on Tax-2 distribution. More
recently, extending these studies to Tax-1, we have shown that
untagged Tax-1 expressed in 293T cells is trapped by CIITA in the
cytoplasm of the majority of cells (Tosi et al., manuscript in prepa-
ration). Similarly to Tax-2, the impaired shuttling of Tax-1 into
the nucleus, may account for the functional inhibition of Tax-1 by
CIITA.
Tax AND CIITA USE COMMON CELLULAR FACTORS TO
CONTROL TRANSCRIPTION OF THEIR TARGET PROMOTERS
Tax interacts with a multitude of cellular factors, forming the
so called Tax interactome, to modulate the expression of viral
and host genes (Boxus et al., 2008; Simonis et al., 2012). Most
of these physical and functional interactions derive from studies
on HTLV-1 Tax-1. Much less is known about the cellular part-
ners mediating Tax-2 biological functions. Notably, many of these
Tax-interacting cellular proteins are used also by CIITA to activate
the transcription of MHC-II promoters. These commonly utilized
factors include transcriptional modulators, chromatin modifying
enzymes, basal transcription factors, and transcription elongation
factors (Table 1).
In addition, Tax and CIITA share several functional fea-
tures. Neither are classical DNA-binding transcription factors,
but instead interact with a platform of DNA-bound proteins to
be recruited to the target promoters. Among them, CREB plays a
major role promoting the formation of a multiprotein complex on
DNA required for the full transcriptional activation (Kwok et al.,
1996; Moreno et al., 1999; Zhu et al., 2000; Lochamy et al., 2007).
In particular, Tax interactionwithCREBdocked at CRE sites of the
viral 21-bp repeats, stabilizes the formation of the ternary com-
plex and recruits the coactivators CBP/p300 and PCAF (Harrod
et al., 1998, 2000; Kashanchi et al., 1998; Jiang et al., 1999). Another
transcription factor that interacts with both Tax and CIITA, is the
B subunit of the NF-Y complex, which binds the inverted CCAAT
sequence in the Y-box of MHC-II promoters (Pise-Masison et al.,
1997; Masternak et al., 2000; Zhu et al., 2000; Jabrane-Ferrat et al.,
2003). While many investigations had assessed the contribution of
NF-Y to class II transcription, no data regarding the speciﬁc role of
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Table 1 | Physical and functional interaction shared byTax and CIITA.
Proteins Function Reference
CREB
NF-YB
Transcriptional activators Kwok et al. (1996), Tosi et al. (2011), Moreno et al. (1999), Lochamy et al. (2007), Zhu et al. (2000).
Pise-Masison et al. (1997), Tosi et al. (2011), Orlandi et al. (2011), Jabrane-Ferrat et al. (2003),
Zhu et al. (2000), Masternak et al. (2000).
TFIID Basal transcription factors Caron et al. (1993), Fontes et al. (1999a).
CBP, p300
PCAF
HDAC1
BRG1
CARM1
Chromatin remodeling factors Harrod et al. (1998, 2000), Kashanchi et al. (1998), Tosi et al. (2006, 2011), Kretsovali et al. (1998),
Fontes et al. (1999b).
Jiang et al. (1999), Tosi et al. (2006), Tosi et al. (2011), Spilianakis et al. (2000).
Ego et al. (2002), Lemasson et al. (2004), Lu et al. (2004), Zika et al. (2003).
Wu et al. (2004) Easley et al. (2010), Zhang et al. (2006), Mudhasani and Fontes (2002).
Jeong et al. (2006), Zika et al. (2005).
P-TEFb Transcription elongation factors Zhou et al. (2006), Cho et al. (2007), Kanazawa et al. (2000).
NF-Y in HTLV transcription were available until recently. We con-
ﬁrmed the association between NF-YB and Tax-1 and extended it
to the Tax-2 transactivator, which binds both to transfected and
endogenous NF-YB in 293T cells (Orlandi et al., 2011; Tosi et al.,
2011). For the ﬁrst time we have shown that the over-expression
of NF-Y signiﬁcantly inhibited Tax-2-driven, but not Tax-1-driven
LTR transactivation (Tosi et al., 2006, 2011). The reasons for this
discrepancy are presently unknown and require further investiga-
tion. These ﬁndings, however, do not conclusively address how
endogenous NF-Y might be important for modulating Tax trans-
activation capacity. It must be stressed that NF-Y is an ubiquitous
factor and, seemingly, its physiologic levels do not impair Tax-2
transcriptional activity, as demonstrated by our Tax-dependent
gene reporter assays performed in 293T/COS cells and by HTLV-2
productive infection of RJ.2.2.5 cells which constitutively express
NF-Y (Tosi et al., 2006, 2011; Orlandi et al., 2011). Neverthe-
less, it is possible that endogenous NF-Y does not allow maximal
Tax-2 transactivation and only its inactivation in cells by the use
of dominant-negative NF-Y vectors or by small interfering RNA
(siRNA; Mantovani et al., 1994; Dolﬁni et al., 2009) will provide
clear evidence of its negative role in LTR promoter activity.
Several families of proteins binding to the Y-box sequence have
been previously identiﬁed (Li et al., 1992; Wolffe et al., 1992).
Besides NF-YB, two other factors called YB-1 and C/EBPβ have
been shown to oppositely regulate HTLV-1 expression. The for-
mer increases the basal LTR transcription (Kashanchi et al., 1994),
the latter, instead, down-regulates Tax-1-mediated transactivation
(Hivin et al., 2004). Thus, distinct family members might exploit
alternative mechanisms to modulate HTLV-2 and/or HTLV-1
transcription.
Several chromatin modifying factors, such as Brahma-related
gene 1 (BRG1) and histone acetyltransferases (HATs) are com-
monly used by Tax andCIITA (Table 1).While it is well established
that the recruitment of HATs to the 21-bp repeats by Tax plays a
critical role in transactivation, it is not clear whether the ATP-
dependent chromatin remodeling factor BRG1, also participates
in Tax-mediated transactivation. Controversial reports have been
published in the past on Tax-1–BRG1 functional interplay. In
one study BRG1 was shown to interact with Tax-1 physically
and functionally and to enhance its capacity to transactivate LTR
promoter (Wu et al., 2004; Easley et al., 2010). On the contrary,
another report indicated that Tax-1-mediated transactivation does
not require BRG1 (Zhang et al., 2006). Interestingly, BRG1 has a
dual action on MHC-II gene expression: (i) it induces CIITA pIV
promoter activation (Pattenden et al., 2002), (ii) it is recruited by
CIITA on MHC-II promoters where, by altering DNA topology,
facilitates the access of general transcription factors and coacti-
vators leading to gene expression (Mudhasani and Fontes, 2002).
Thus the role of BRG1 in the regulation of HTLV-1 replication in
presence of CIITA certainly requires further investigation.
The HATs p300, CBP, and PCAF participate with CIITA to the
formation of an active MHC-II enhanceosome (Kretsovali et al.,
1998; Fontes et al., 1999b). Moreover, they also catalyze the acety-
lation of CIITA at twoN-terminal lysine residues within a bipartite
nuclear localization signal (NLS). Acetylation or inhibition of
deacetylation by Trichostatin A leads to increased nuclear levels
of CIITA and higher transactivation of class II genes (Spilianakis
et al., 2000). Remarkably, CIITA also contains an HAT activity,
which is required for IFN-γ-activatedMHC-I andMHC-II expres-
sion (Raval et al., 2001).While the transcriptional activity of CIITA
is linked to the recruitment of HATs on class II promoters, his-
tone deacetylation correlates with transcriptional repression and
is mediated by distinct histone deacetylase (HDAC) complexes.
HDAC1/HDAC2 stably associated with the mSin3A corepressor
bind to CIITA and inhibits its transactivating function through
a disruption of MHC-II enhanceosome (Zika et al., 2003). As far
as the involvement of HATs in Tax-mediated HTLV transcription,
our studies revealed functional differences among the HAT fam-
ily members interacting with Tax-1 and Tax-2. In particular, we
conﬁrmed that HTLV-1 and HTLV-2 gene transcription is syn-
ergistically enhanced by the interaction of CBP/p300 with both
Tax-1 and Tax-2. In contrast, Tax-1 but not Tax-2 selectively uses
PCAF to optimally transactivate HTLV-1 LTR (Tosi et al., 2006,
2011). This effect is independent from the enzymatic activity
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of PCAF, which might instead engage other coactivators (Jiang
et al., 1999). A selective usage of HATs by the two viral trans-
activators has been previously demonstrated for the inhibition
of p53 by Meertens et al. (2004b). The different requirement for
PCAF between Tax-1 and Tax-2 implies that only Tax-1 might
affect nuclear PCAF-containing complexes, potentially contribut-
ing to the pleiotropic de-regulated expression of cellular genes
during T cell transformation. Of note, a reduced transactiva-
tion and a defective cellular transformation have been observed
with Tax-1 mutants which poorly interact with PCAF (Smith and
Green, 1990; Jiang et al., 1999). These observations further sup-
port the idea that the higher oncogenic potential of Tax-1 with
respect to Tax-2 might be, at least in part, attributed to a peculiar
utilization of HATs. Similarly to CIITA, Tax-1 interacts with sev-
eral HDACs including HDAC1, HDAC3, and HDAC6 (Villanueva
et al., 2006; Legros et al., 2011). HDAC1 binding negatively regu-
lates the HTLV-1 gene expression (Ego et al., 2002; Lemasson et al.,
2004). Nevertheless, Tax-1 has been shown to replace HDAC1 on
LTR promoter allowing transcription initiation (Lu et al., 2004).
Thus, both CIITA and Tax may act as a molecular switch, to mod-
ulate transcription by coordinating the function of both HATs
and HDACs. Besides the roles for HATs and HDAC, more recently
arginine-speciﬁc methylation of histones has emerged as a critical
feature for both MHC-II and HTLV-1 transcriptional regulation.
The coactivator-associated argininemethyltransferase 1 (CARM1)
has been reported to interact and synergize with both CIITA and
Tax-1 to optimally activate transcription of their target genes (Zika
et al., 2005; Jeong et al., 2006). Aside from their interactions with
speciﬁc DNA-bound factors and chromatin modifying proteins,
Tax and CIITA bind also component of the general transcriptional
machinery, such as TFIID, to direct transcription initiation (Caron
et al., 1993; Fontes et al., 1999a). There is also evidence that both
transcription factors recruit the P-TEFb to the target promoters
by interacting with the cyclin T1 subunit (Kanazawa et al., 2000;
Zhou et al., 2006; Cho et al., 2007).
Overall, the ﬁndings discussed above highlight the central
role of both Tax and CIITA in transcription through the coor-
dination of enhanceosome complex assembly and the control of
transcription initiation and elongation.
CIITA EXPLOITS DIFFERENT MOLECULAR MECHANISMS TO
INHIBIT THE VIRAL TRANSACTIVATORS Tax-1 AND Tax-2
On the basis of what has been described in the previous section,
the hypothesis that the physical interaction between CIITA and
Tax may solely account for the observed CIITA-mediated inhibi-
tion of Tax-dependent LTR transactivation could reﬂect only part
of the complex molecular interplay between the viral and cellular
transactivators. Thus, we hypothesized that CIITA might inhibit
Tax-mediated transcription also by sequestering one or more of
those factors that are commonly used by CIITA and Tax for their
speciﬁc transcriptional regulatory functions. This idea was fur-
ther supported by our previous ﬁnding that CIITA inhibits HIV-1
replication by competing with Tat for the binding to cyclin T1 of
P-TEFb complex (Accolla et al., 2002). Moreover, it is known that
the sequestration of HATs is a commonmechanism throughwhich
CIITA mediates gene suppression. For instance, CIITA by binding
to and sequestering CBP inhibits metalloproteinase-9, collagen α
2(I), thymidine kinase, and cyclin D1 gene expression (Zhu and
Ting, 2001; Nozell et al., 2004). In addition, CIITA by competing
with NFAT (nuclear factor of activated T-cells) for p300 bind-
ing, represses the expression of IL-4 (Sisk et al., 2000). Similarly,
CIITA exerts a repressive effect on Cathepsin E expression most
likely via interaction with p300 (Yee et al., 2004). For these rea-
sons we assessed whether the over-expression of some of these
commonly used factors could rescue Tax function inhibited by
CIITA. Whereas the over-expression of HATs did not overcome
Tax-2 suppression, the over-expression of PCAF, but not of p300,
counteracted the inhibitory function of CIITA on Tax-1 (Tosi
et al., 2006, 2011). These data imply that CIITA might inhibit
the recruitment of PCAF to the transcriptional complex on the
viral promoter simply by sequestering it (Figure 4A). Nevertheless,
another possibility is that the intrinsic ability of CIITA to interact
with Tax-1, could impair Tax-1–PCAF association (Figure 3C).
Indeed, CIITA decreased the in vivo binding of PCAF to Tax-1
(Tosi et al., 2011). CIITA and PCAF bind to two distinct regions of
Tax-1 localized at the N-terminus and at the C-terminus, respec-
tively (Jiang et al., 1999; Tosi et al., 2011) indicating that PCAF
and CIITA do not compete for the same binding surface of Tax-1.
Rather, the binding of CIITA to Tax-1 might alter the confor-
mation of the viral transactivator masking the binding surface to
PCAF.
Besides PCAF, the over-expression of CREB and ATF1 tran-
scription factors restored CIITA-inhibited Tax-1 transactivation.
Because the N-terminal region of Tax-1 interacting with CIITA
includes CREB-binding site (Wu et al., 2004; Tosi et al., 2011),
it is not surprising that the two factors compete for Tax-1.
In the presence of CIITA, CREB might be no longer available for
the recruitment of Tax-1 on the 21-bp repeats, thus preventing
the assembly of the multiprotein complex required for optimal
HTLV-1 LTR transactivation (Figure 4A).
Overall, these results indicate relevant differences in CIITA-
mediated suppression of Tax-1 and Tax-2. The sequestration of
HATs is not the major mechanism through which CIITA inhibits
Tax-2, which, as discussed above, is functionally suppressed by
NF-Y, another essential component of MHC-II enhanceosome.
FIGURE 4 | Distinct mechanisms account for CIITA-mediated inhibition
of HTLV-1Tax-1 and HTLV-2Tax-2. (A)The cellular factors PCAF and
CREB/ATF, required for CIITA-mediated MHC-II transcription, are
sequestered by CIITA and are no longer available to interact physically
and functionally with Tax-1. This results in the inhibition of HTLV-1 LTR
transactivation (−). (B) CIITA facilitates the interaction betweenTax-2
and NF-Y, an inhibitor of Tax-2 transcription function.
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Interestingly, NF-Y cooperates with CIITA to inhibit Tax-2 trans-
activating function suggesting that CIITA might behave as a
bridging factor to assemble a defective Tax-2/CIITA/NF-Y tran-
scriptional complex (Tosi et al., 2006; Figure 4B). It has been
reported that NF-Y interacts with PCAF (Currie, 1998) and it is
intriguing that the two factors differently affect the transcriptional
function of Tax-1 and Tax-2. Tax-1-mediated LTR transcrip-
tion is enhanced by PCAF, but is not affected by NF-Y. On the
contrary, Tax-2-mediated LTR transcription is inhibited by over-
expressed NF-Y, but is not increased by PCAF. In this context
CIITA seems to exploit the two players to exert its inhibitory
function on the viral transactivators by inhibiting the inter-
action between Tax-1 and its positive coactivator PCAF, while
increasing the binding of Tax-2 to its negative regulator NF-Y
(Orlandi et al., 2011).
Future efforts will be devoted to assess whether CIITA inhibits
Tax by sequestering other commonly used factors or by inhibiting
their physical interaction with Tax-1 and/or Tax-2. At the present
we can only exclude competition betweenCIITA andTax for cyclin
T1-binding. Indeed, the region of CIITA mediating Tat suppres-
sion differs from that required to inhibit both Tax-1 and Tax-2,
indicating that CIITA blocks HIV-1 and HTLVs through different
molecular mechanisms (data not shown).
CONCLUSION
In this review we provided an update on the anti-viral features
that make CIITA a fundamental link between adaptive and intrin-
sic immunity against HTLV infections. By inducing MHC-II
expression and, thus, antigen presentation, CIITA triggers the
activation of TH cells, which, in turn, orchestrate the adaptive
immune responses against pathogens. In addition, CIITA has a
direct inhibitory effect on the replication of HTLV-1 and HTLV-2
retroviruses by suppressing the transcriptional function of their
viral transactivators. CIITA exploits different ways to exert this
latter inhibitory function: it binds Tax-1 and Tax-2; it speciﬁ-
cally modulates the interaction of Tax-1 and Tax-2 with relevant
cellular factors; and it affects the subcellular localization of the
two viral transactivators. Thus, CIITA seems to have evolved
multiple strategies to be more effective in the inhibition of Tax
function. It is known that other host restriction factors may target
different steps of viral life cycle to block HIV-1 infection. Nev-
ertheless, the restriction is more effective in species other than
the human species, because HIV-1 has developed countermea-
sures against these innate defenses. In contrast, CIITA is a peculiar
restriction factor because restricts HIV-1, HTLV-1, and HTLV-2
in their natural host (Accolla et al., 2002; Casoli et al., 2004; Tosi
et al., 2011). So far, no viral products are known to counteract
CIITA-mediated restriction. On the contrary, it is well known
that some bacteria (e.g., Mycobacteria and Chlamydia) and some
viruses (e.g., human cytomegalovirus and Varicella zoster) cause
a reduction of MHC-II molecules on the surface of parasitized
cells by inhibiting the pathway leading to the activation of CIITA
gene transcription (Accolla et al., 2001). Thus, also HIV-1 and
HTLV viruses might have evolved mechanisms to evade the host’s
immune system based on the suppression of CIITA expression
and/or function. At least for HIV-1 infection, our previous results
indicated that Tat had no effect on both MHC-II and CIITA
expression in T and macrophage cell lines (Tosi et al., 2000). As
far as HTLV-1, it has been reported that Tax-1 increases basal
MHC-II transcription by interacting with NF-YB (Pise-Masison
et al., 1997). Moreover, a putative functional effect of Tax-1 on
CIITA-mediated MHC-II gene expression, although unlikely, has
not been investigated in detail as yet. Future investigation will
thus uncover also the possible complementary role that both
Tax-1 and Tax-2 might play a role in CIITA-dependent MHC-II
transcription.
HTLV-1 and HTLV-2 viruses preferentially infect and repli-
cate in human T lymphocytes, which express MHC-II molecules
upon activation. It must be stressed, however, that whereas the
expression of MHC-II molecules on the cell surface last for several
days, CIITA expression is time-limited because of its very short
half-life (Schnappauf et al., 2003). Thus, sustained expression of
CIITA might be required to control HTLV replication. Interest-
ingly, as discussed above, cell surface MHC-II molecule expression
in mature DCs is up-regulated, whereas the expression of CIITA is
silenced. This might, at least in part, explain why HTLV-1 produc-
tive infection is not counteracted in DCs (Jones et al., 2008). These
ﬁndings disclose the opportunity of developing new therapeutic
approaches against HTLV infections based on biological and/or
pharmacological strategies aimed at up-regulating, in a controlled
manner, the expression of CIITA in cells that are targeted by the
virus.
Besides its role as transcriptional activator of HLTV genome
transcription, Tax plays a major role in viral pathogenesis and T
cell immortalization (Grassmann et al., 1989; Ross et al., 2000).
Tax deregulates the expression of cellular genes mostly by the
constitutive activation of NF-kB pathway and the inhibition of
p53 tumor suppressor (Pise-Masison et al., 1998; Li and Gaynor,
2000; Mahieux et al., 2000; Miyazato et al., 2005; Peloponese et al.,
2006; Qu and Xiao, 2011). It is conceivable that CIITA might
exert a broader effect on HTLV infection by counteracting Tax
oncogenic potential. Future efforts will be devoted to investigate
whether CIITA inhibits Tax-mediated NF-kB activation and p53
suppression.
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